Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205917 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03205917 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 29 participants.
The verdict
NCT03205917, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
Interventions
- BIOLOGICAL PGDM1400/Placebo (3mg/kg IV)
- BIOLOGICAL PGDM1400/Placebo (10mg/kg IV)
- BIOLOGICAL PGDM1400/Placebo (30mg/kg IV)
- BIOLOGICAL PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)
- BIOLOGICAL PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205917
The ClinicalTrials.gov registry entry for NCT03205917 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PGDM1400/Placebo (3mg/kg IV) is the first listed.
NCT03205917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03205917 about?
NCT03205917 is a clinical study titled "A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults". This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
What is the current status of trial NCT03205917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-10-23. Estimated completion is 2020-04-20.
What interventions are being tested in trial NCT03205917?
The interventions under investigation include: PGDM1400/Placebo (3mg/kg IV) (BIOLOGICAL), PGDM1400/Placebo (10mg/kg IV) (BIOLOGICAL), PGDM1400/Placebo (30mg/kg IV) (BIOLOGICAL), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV) (BIOLOGICAL), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03205917?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.